Interleukin-17: A potential therapeutic target in COVID-19
- PMID: 32504739
- PMCID: PMC7834707
- DOI: 10.1016/j.jinf.2020.05.072
Interleukin-17: A potential therapeutic target in COVID-19
Keywords: COVID-19; IL-17; cytokine storm; immunomodulatory therapy; lung injury.
Conflict of interest statement
Declaration of Competing Interest None.
Figures
Comment in
-
REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19.J Infect. 2020 Sep;81(3):e37-e38. doi: 10.1016/j.jinf.2020.06.063. Epub 2020 Jun 29. J Infect. 2020. PMID: 32610110 Free PMC article. No abstract available.
Comment on
-
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10. J Infect. 2020. PMID: 32283152 Free PMC article. Review.
References
-
- Yingxia Liu, Cong Zhang, Fengming Huang, Yang Yang, Fuxiang Wang, Yuan Jing. 2019-novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury. ChinaXiv. 2020 doi: 10.12074/202002.00018. - DOI
-
- Mahesh Manjunath Gouda, Prabhakar Bhandary Yashodhar. IL-17A Mediated Downstream Changes During Acute Lung Injury. Biochem Mol Biol J. 2018;04(02) doi: 10.21767/2471-8084.100062. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources